Bioxytran, Inc.
BIXT
$0.1567
-$0.0054-3.33%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.30% | -22.98% | 56.09% | 135.56% | 129.53% |
| Depreciation & Amortization | -4.82% | 62.96% | 102.22% | 206.25% | 130.56% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.36% | -23.18% | 31.19% | 85.99% | 78.33% |
| Operating Income | 41.36% | 23.18% | -31.19% | -85.99% | -78.33% |
| Income Before Tax | 46.71% | 31.77% | -10.77% | -77.97% | -68.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.71% | 31.77% | -10.77% | -77.97% | -68.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -70.54% | -70.65% | -57.46% | -59.65% | -53.31% |
| Net Income | 46.22% | 30.66% | -14.31% | -88.28% | -77.94% |
| EBIT | 41.36% | 23.18% | -31.19% | -85.99% | -78.33% |
| EBITDA | 41.43% | 23.31% | -31.07% | -85.81% | -78.23% |
| EPS Basic | 47.87% | 42.11% | 5.56% | -59.69% | -53.27% |
| Normalized Basic EPS | 31.68% | 41.92% | 3.95% | -64.96% | -57.81% |
| EPS Diluted | 47.87% | 42.11% | 5.56% | -59.69% | -53.27% |
| Normalized Diluted EPS | 31.68% | 41.92% | 3.95% | -64.96% | -57.81% |
| Average Basic Shares Outstanding | 4.18% | 19.79% | 26.71% | 21.43% | 16.24% |
| Average Diluted Shares Outstanding | 4.18% | 19.79% | 26.71% | 21.43% | 16.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |